Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis
Prostate Cancer · 2026-01 · 2026 (1)
DOI: 10.1155/proc/9470087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prostate Cancer, online erschienen am 20.08.2026. Verfasst von Wafa D Aloufi und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Dundee School of Medicine, Dundee, UK. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taif University.
Abstract (Originalsprache)
Background mpMRI is now widely used before prostate biopsy and has improved the detection of clinically significant prostate cancer (csPCa). However, the subsequent risk of csPCa among men with both negative mpMRI and negative systematic biopsy (SBx) remains uncertain.
Purpose
To evaluate the observed medium‐term risk of csPCa in biopsy‐naïve men with initially negative mpMRI and negative SBx.
Methods
This post hoc longitudinal follow‐up subanalysis included biopsy‐naïve men from the prospective multicenter MULTIPROS trial who had negative baseline mpMRI (PI‐RADS ≤ 2) and negative SBx. Of the 582 enrolled men, 169 had negative mpMRI; 138 underwent baseline SBx, of whom 8 had csPCa, and 31 had < 12 months of follow‐up, leaving 99 men for analysis. Follow‐up was PSA‐based, with repeat mpMRI and biopsy performed when clinically indicated. Kaplan–Meier analysis estimated csPCa‐free survival.
Results
During a mean follow‐up of 61.8 ± 22.1 months, four patients were diagnosed with csPCa (4/99; 4.0%). The mean time from initial negative mpMRI to csPCa diagnosis was 68.3 ± 22.4 months. Repeat biopsy was performed in 16 patients. csPCa‐free survival was 100% at 24 months and 97.3% at 60 months (95% CI: 93.7%–100%).
Conclusion
In this selected cohort of biopsy‐naïve men with both negative mpMRI and negative SBx, the observed incidence of csPCa during medium‐term follow‐up was low but based on only four events. Because repeat imaging and biopsy were selectively triggered rather than systematically performed, the true incidence of csPCa may be underestimated. Continued PSA‐based monitoring, with repeat mpMRI and biopsy when clinically indicated, remains important.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Dundee School of Medicine, Dundee, UK.
- Taif University, Taif, Makkah Province, Saudi Arabia, tu.edu.sa.
- Division of Population Health and Genomics, University of Dundee, Dundee, UK, dundee.ac.uk.
- Ninewells Hospital and Medical School, Dundee, UK, dundee.ac.uk.
ORCID-Profile: Wafa D Aloufi, Magdalena Szewczyk-Bieda, Cheng Wei, Luigi Manfredi
Förderung
- Taif University
Zitieren
APA
Aloufi, W. D., Zhang, X., Szewczyk-Bieda, M., Nabi, G., Wei, C., & Manfredi, L. (2026). Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis. Prostate Cancer, 2026(1). https://doi.org/10.1155/proc/9470087
Vancouver
Aloufi WD, Zhang X, Szewczyk-Bieda M, Nabi G, Wei C, Manfredi L. Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis. Prostate Cancer. 2026;2026(1). doi:10.1155/proc/9470087
BibTeX
@article{Aloufi2026,
author = {Aloufi, Wafa D and Zhang, Xinyu and Szewczyk-Bieda, Magdalena and Nabi, Ghulam and Wei, Cheng and Manfredi, Luigi},
title = {Long‐Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy‐Naïve Men: A MULTIPROS Subanalysis},
journal = {Prostate Cancer},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/proc/9470087}
}
EUVIMED